Affiliations: Jindal Global Law School, O.P. Jindal Global
University, SonipatNarelaRoad, Near Jagdishpur Village, Sonipat,
Haryana-131001, India. Tel.: +91 130 3057920; Fax: +91 130 3057888; E-mail:
[email protected]/[email protected]
Abstract: Borderline medical products have continued to pose as a challenge to
regulators of cosmetics, medical devices and pharmaceutical products in Europe.
Borderline products refer to products that exhibit multiple product
characteristics and therefore could potentially straddle a minimum of two
product regulatory categories. Legislation solutions in the form of the `rule
of doubt' provisions function on the principle of adoption of a higher burden
in case of confusion exist. Although they do provide immediate solutions, they
fail in ensuring legal certainty to all the principal stakeholders. This
article discusses the jurisprudence on borderline products based on national
and European case law. While this jurisprudence clarifies several regulatory
points of conflict, it is in many ways limited. Questions of regulatory
categorization are essentially science questions – that are evolving – and
are therefore bound to escape determinative categories propounded within
European regulations. The solution lies in appreciating the role played by
deliberative institutional networks that are active contributors of regulatory
disciplines and ensuring mechanisms by which judges will be able to access
scientific knowledge on this issue.
Keywords: Regulation, Europe, pharmaceutical, medical devices, cosmetics, case law, borderline products